对《药物转运体OCT2的表观遗传激活使肾细胞癌对奥沙利铂敏感》评论的回应 - Suppr | 超能文献

相似文献

1

Response to Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".对《药物转运体OCT2的表观遗传激活使肾细胞癌对奥沙利铂敏感》评论的回应

Sci Transl Med. 2017 May 24;9(391). doi: 10.1126/scitranslmed.aam6298.

2

Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".关于“药物转运体OCT2的表观遗传激活使肾细胞癌对奥沙利铂敏感”的评论

Sci Transl Med. 2017 May 24;9(391). doi: 10.1126/scitranslmed.aal2439.

3

Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.表观遗传激活药物转运蛋白 OCT2 可使肾细胞癌对奥沙利铂敏感。

Sci Transl Med. 2016 Jul 20;8(348):348ra97. doi: 10.1126/scitranslmed.aaf3124.

4

Kidney cancer: OCT2 demethylation cracks open oxaliplatin resistance.

Nat Rev Nephrol. 2016 Oct;12(10):581. doi: 10.1038/nrneph.2016.122. Epub 2016 Aug 8.

5

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.氟尿嘧啶、亚叶酸钙、奥沙利铂和伊立替康联合治疗肾盂尿路上皮癌疗效显著：一例报告

J Med Case Rep. 2017 Apr 10;11(1):99. doi: 10.1186/s13256-017-1263-x.

6

HNF4α induced chemosensitivity to oxaliplatin and 5-FU mediated by OCT1 and CNT3 in renal cell carcinoma.

J Pharm Sci. 2014 Oct;103(10):3326-34. doi: 10.1002/jps.24128. Epub 2014 Aug 29.

7

Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx.塞来昔布通过损害药物内流来拮抗奥沙利铂在人食管癌细胞中的细胞毒性。

Eur J Pharm Sci. 2016 Jan 1;81:137-48. doi: 10.1016/j.ejps.2015.10.009. Epub 2015 Oct 22.

8

Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma.靶向miR-21可降低多药耐药基因的表达并提高肾癌的化疗敏感性。

Tumour Biol. 2017 Jul;39(7):1010428317707372. doi: 10.1177/1010428317707372.

9

β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.β-榄香烯通过阻止奥沙利铂诱导的铜转运蛋白1降解，使肝癌细胞对奥沙利铂敏感。

Sci Rep. 2016 Feb 12;6:21010. doi: 10.1038/srep21010.

10

A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma.

Oncology. 2003;64(1):25-7. doi: 10.1159/000066518.

引用本文的文献

1

Vascular dysfunction is at the onset of oxaliplatin-induced peripheral neuropathy symptoms in mice.血管功能障碍是奥沙利铂诱导的小鼠周围神经病变症状的起始点。

Life Sci Alliance. 2024 Nov 22;8(2). doi: 10.26508/lsa.202402791. Print 2025 Feb.

2

Nanomaterial-related hemoglobin-based oxygen carriers, with emphasis on liposome and nano-capsules, for biomedical applications: current status and future perspectives.基于纳米材料的血红蛋白氧载体，重点是脂质体和纳米胶囊，用于生物医学应用：现状和未来展望。

J Nanobiotechnology. 2024 Jun 16;22(1):336. doi: 10.1186/s12951-024-02606-1.

3

The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.